Literature DB >> 12635877

Comparison of magnesium and zinc levels in blood in end stage renal disease patients treated by hemodialysis or peritoneal dialysis.

Irena Pietrzak1, Katarzyna Bladek, Wlodzimierz Bulikowski.   

Abstract

The abnormal metabolism of macrominerals and trace metals, a frequently overlooked fact may be one of the factors influencing clinical disorders in chronic dialysis patients. The purpose of this study was to compare to what extent maintenance hemodialysis (HD) and continuous ambulatory peritoneal dialysis (CAPD) therapy influences the magnesium (Mg) and zinc (Zn) levels in blood of patients treated by these two methods. Additionally, we examined the influence of rhEPO therapy on Hb concentration in erythrocytes, total protein and albumin levels in plasma, and possible impact of rhEPO on Zn and Mg content in blood. Seventy-five ESRD (25 treated and 15 non treated with rhEPO on HD), and (20 treated and 15 non treated with rhEPO on CAPD) patients participated in this study. Forty-five healthy volunteers (HV) served as a reference group. The mean plasma and erythrocytes Mg concentration (mmol/l) in HD and CAPD patients without and with rhEPO treatment was found to be significantly higher than in HV. In HD and CAPD patients treated by rhEPO the mean erythrocytes Mg levels were significantly lower than in non rhEPO treated groups. The inverse relationship between Hb and Mg concentration in erythrocytes in HD and CAPD patients with rhEPO treatment was observed (r = -0.63, P < 0.05 and r = -0.59, P < 0.01 respectively). The mean plasma Zn levels (micromol/l) in HD and CAPD patients with and without rhEPO have been significantly lower than in HV. In patients treated by rhEPO significant increase of Zn erythrocytes levels was found. We was found positive correlation between plasma and erythrocyte Zn levels and Hb concentration in HD and CAPD patients treated by rhEPO (r = 0.35, P < 0.05 and r = 0.4, P < 0.05 respectively). The Hb concentrations, total protein and albumin levels in HD and CAPD with rhEPO therapy were found significantly higher than in patients without rhEPO therapy, but still lower if compared to HV. Mean levels of iron and TIBC in plasma have been found significantly lower in both studied groups treated or non treated by rhEPO, in comparison to HV. In both studied groups of patients without rhEPO or treated by rhEPO plasma GC, GSA, Cr concentrations were significantly higher from those obtained in HV. No statistical correlations were found between Mg, Zn and total protein, albumin, iron levels and TIBC. During rhEPO therapy increased Hb concentration was connected with higher plasma and erythrocytes Zn levels and lower erythrocytes Mg levels. rhEPO may improve the Mg and Zn disturbed metabolism in uraemia.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12635877

Source DB:  PubMed          Journal:  Magnes Res        ISSN: 0953-1424            Impact factor:   1.115


  4 in total

1.  Serum zinc and copper levels in children with chronic renal failure.

Authors:  Seyed Taher Esfahani; Mohammad Reza Hamidian; Abbas Madani; Neamatollah Ataei; Parvin Mohseni; Moustafa Roudbari; Marzieh Haddadi
Journal:  Pediatr Nephrol       Date:  2006-06-22       Impact factor: 3.714

2.  Comparative evaluation of essential and toxic elements in the blood of kidney failure patients and healthy referents.

Authors:  Abdul Haleem Panhwar; Tasneem Gul Kazi; Hassan Imran Afridi; Salma Aslam Arain; Mariam S Arain; Kapil Dev Brahman; Naeem Ullah; Jamshed Ali; Sadaf Sadia Arain
Journal:  Environ Monit Assess       Date:  2015-01-30       Impact factor: 2.513

3.  Magnesium in chronic kidney disease Stages 3 and 4 and in dialysis patients.

Authors:  John Cunningham; Mariano Rodríguez; Piergiorgio Messa
Journal:  Clin Kidney J       Date:  2012-02

Review 4.  Trace elements in hemodialysis patients: a systematic review and meta-analysis.

Authors:  Marcello Tonelli; Natasha Wiebe; Brenda Hemmelgarn; Scott Klarenbach; Catherine Field; Braden Manns; Ravi Thadhani; John Gill
Journal:  BMC Med       Date:  2009-05-19       Impact factor: 8.775

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.